Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent
autologous transplantation in patients with non-Hodgkin's lymphoma and
multiple myeloma.
CRP Levels Before Transplant Linked With Survival in
Multiple Myeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an autologous stem cell transplantation (ASCT) for multiple myeloma experienced a worse overall survival (O
Multiple Myeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an
autologous stem cell
transplantation (ASCT) for
multiple myeloma experienced a worse overall survival (O
multiple myeloma experienced a worse overall survival (OS) rate.